Semaglutide onset of action: when does it actually start working?

Week one: you've taken your first dose — here's what's happening inside

Picture the morning after your first Wegovy injection. You may feel nothing unusual at all, or you might notice a very slight reduction in appetite by day two or three. Both are normal. Semaglutide is a GLP-1 receptor agonist, and if you want to understand how semaglutide acts once it enters your system, from the receptors it targets to the hormonal signals it sets in motion, it mimics a gut hormone that signals fullness to the brain and slows the rate at which your stomach empties. Once absorbed, it starts binding to GLP-1 receptors relatively quickly, peak plasma concentration arrives within one to three days of a subcutaneous injection.

What it is not doing at this stage is producing dramatic weight loss. The starting dose (0.25 mg for the weekly injection) is a tolerability dose. Its job is to let your digestive system adjust rather than to deliver the full therapeutic effect. Think of it as your system learning the signal before it responds to it fully. Side effects such as mild nausea or loose stools are most common now, precisely because your gut is encountering a new level of GLP-1 activity. The NHS medicines page for semaglutide covers this early GI profile in plain terms and is worth reading before you begin.

One thing our prescribers hear most weeks: patients asking whether the absence of dramatic early changes means something is wrong. It almost never does. The pharmacology is simply playing a longer game.

Weeks four to twelve: when the Wegovy onset of action becomes visible on the scales

By week four or five, steady-state semaglutide levels are established in the bloodstream, meaning the concentration no longer fluctuates wildly between doses. Many people notice a more consistent reduction in appetite and portion sizes around this point. You may find you feel full sooner, think about food less between meals, or lose interest in snacks you previously reached for automatically.

This is also the period when most titration steps happen, moving from 0.25 mg to 0.5 mg and then 1.0 mg at roughly four-weekly intervals under your prescriber's review. Each step up typically brings a modest increase in appetite suppression. Weight loss that is measurable on the scales tends to appear somewhere between weeks eight and twelve for many people, though the pace varies considerably depending on starting weight, diet, activity level and individual metabolism. The STEP 1 trial (published in the New England Journal of Medicine) randomised over 1,900 adults and found an average body-weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose alongside lifestyle changes, with weight loss continuing to accumulate well past the first three months.

Patience during this window is genuinely useful. Stopping too soon because the scales haven't shifted in week six misses most of the clinical benefit.

Month three and beyond: where semaglutide's weight-management effect compounds

Once you reach and maintain a therapeutic dose (1.7 mg or 2.4 mg weekly for the injection, depending on your prescriber's judgement) weight loss tends to accelerate and then plateau as your body reaches a new equilibrium. This is consistent with what the NICE appraisal of semaglutide (TA875) reviewed when recommending it for use within specialist weight management services: the greatest proportional losses cluster in the first twelve to eighteen months, after which a plateau is common.

A few practical points about this phase. Some people reach their maintenance dose relatively smoothly; others need to pause a titration step because of GI side effects, which is clinically normal and does not mean the medicine has failed. Your prescriber re-reviews your progress before each repeat supply, which is one reason clinical supervision throughout this period matters rather than simply collecting pens and self-managing. If you are weighing up your options for different approaches to weight management, it helps to know that semaglutide's full effect is genuinely a long-range story.

The new oral form, Wegovy tablets, follows a similar gradual logic, a different dosing ladder, a different absorption route, but still a progressive timeline shaped by titration and steady-state pharmacology. If you are curious about how Wegovy produces its effects once it is active in the body, that explains the biology behind the lag.

What affects how quickly semaglutide works for you personally

The population averages from trials are useful reference points, but they mask real variation. Several factors influence how quickly an individual notices the onset of semaglutide's effects. Gastric emptying rates differ between people; someone whose stomach empties more slowly to begin with may notice the slowing effect less acutely. Starting weight matters too: a larger absolute loss in kilograms can occur even when the percentage reduction is comparable to someone lighter, simply because the base is higher.

Diet and physical activity alongside treatment are not incidental. The STEP 1 trial paired semaglutide with reduced-calorie eating and increased movement, and the results reflect that combination. Semaglutide quiets appetite signals; it does not replace the need for energy balance. Individual responses to GI side effects also shape the practical timeline, someone who experiences significant nausea may need their titration slowed, which pushes back the point at which the full maintenance-dose effect kicks in.

There is also the question of interactions and situations that require prescriber input, such as planned surgery, which can affect how treatment is managed during the relevant window. For a fuller picture of the medicine itself, the Wegovy overview covers licensing, eligibility and how the injectable and tablet forms compare. When you are ready to have your own timeline assessed properly, speaking to our prescribers is the place to start, and reading about the mechanisms behind semaglutide's appetite and metabolic effects can give you a useful grounding before that conversation.